“We write to emphasize the urgent need for Congress to take action," the Medical Group Management Association wrote to House and Senate leaders Dec. 19.
Telix Pharmaceuticals recently submitted its license application to the FDA for the investigational positron emission tomography agent TLX250-CDx (Zircaix).